1045 Dual-antigen cancer vaccine co-targeting human PD-L1 and PRAME induces specific immune responses in hPD-1/hPD-L1/HLA-A2.1 mice and inhibits tumor growth in an HLA-A2.1/hPRAME mouse colon cancer model
Year: 2026
Type: conference-abstract
Abstract: Background Human immune checkpoint antigen Programmed death-ligand 1 (hPD-L1) and the cancer-testis antigen Preferentially expressed antigen in melanoma (hPRAME) were utilized to construct a dual-antigen cancer vaccine. Its anti-cancer activity was evaluated in hPD-1/hPD-L1/HLA-A2.1 mice and in an HLA-A2.1/hPRAME MC38 syngeneic mouse colon cancer model, assessing immune response induction, tumor growth inhibition, modulation of the tumor microenvironment and long-term protection against tumor rechallenge.Methods The dual-antigen cancer vaccine and its murine surrogate with mouse PD-L1 were expressed and purified from bacterial cells. The protein vaccines (30 µg/dose) were formulated with CpG oligodeoxynucleotide (30 µg/dose) and Alhydrogel (300 µg/dose) for subcutaneous vaccination of hPD-1/hPD-L1/HLA-A2.1 mice (n = 8/group), administered four times biweekly before serum and splenocyte collection for antibody response (ELISA) and T-cell response (ELISpot) assessment, respectively. To assess the tumor growth inhibition effect, HLA-A2.1 mice (n = 10/group) were vaccinated twice before implantation of HLA-A2.1/hPRAME MC38 colon cancer cells, followed by two booster doses. At the end of the tumor growth inhibition study, serum, splenocytes and tumor tissues were collected to assess immune responses and changes in the tumor microenvironment. Moreover, vaccinated tumor-free mice (n = 3/group) were monitored for tumor recurrence over three months and then subjected to tumor rechallenge to evaluate long-term protection.Results Vaccination of hPD-1/hPD-L1/HLA-A2.1 mice with the adjuvanted human dual-antigen cancer vaccine or its murine surrogate with mouse PD-L1 induced species-matched anti-human PD-L1 and anti-mouse PD-L1 antibody responses (titers reached 1:16,000), respectively, as well as a robust hPRAME specific T-cell response. In the HLA-A2.1/hPRAME MC38 mouse colon cancer model, the dual-antigen cancer vaccine induced specific immune responses against both human antigens and demonstrated 65% tumor growth inhibition compared to the adjuvant control group ( p < 0.01). Immunohistochemistry demonstrated significant increase of tumor-infiltrating CD4-positive cells in the vaccinated mice (p < 0.05) and real-time qPCR analysis of the tumor tissues revealed more than a two-fold increase of the immune activation cytokines interferon-γ (p < 0.05), the cytotoxic effector molecule granzyme B (p < 0.01), as well as more than a five-fold reduction of the M2 tumor associated macrophage marker CD163 (p < 0.001), indicating modulation of the tumor microenvironment after vaccination. Moreover, the cancer vaccine elicited a durable antigen-specific immune response, protecting the mice against tumor rechallenge.Conclusions The results of this preclinical study demonstrate the anti-cancer vaccine efficacy and long-term protective effects of our dual-antigen cancer vaccine in humanized mouse models, further supporting its potential for clinical development.Ethics Approval This study was approved by the IACUC of Biocytogen Pharmaceuticals (Beijing) Co. Ltd.; approval number PS-01-2602071.
Authors: Kin-Tak Chan, Melvin Toh
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W7225166384
